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anticancer activity and QSAR studies†
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An efficient method is proposed for obtaining tetrahydrobenzo[a]xanthene-11-ones and tetrahydro-[1,3]-
dioxolo[4,5-b]xanthen-9-ones. The method is based on the use of p-sulfonic acid calix[n]arenes as cata-
lysts under solvent-free conditions. The antiproliferative activity of fifty-nine xanthenones against six
human cancer cells was studied. The capacity of all compounds to inhibit cancer cell growth was depen-
dent on the histological origin of the cells. QSAR studies indicate that among compounds derived from
β-naphthol the most efficient compounds against glioma (U251) and renal (NCI-H460) cancer cells are
those having higher hydrogen bonding donor ability.
Introduction
Cancer is an important public health concern and a leading
cause of death. It accounted for eight million deaths world-
wide (ca. 15% of all deaths) in 2010 (38% more than in
1990).1,2 Many of the current chemotherapy drugs have low
specificity for tumor cancer cells, and are also toxic to normal
cells. The inefficiency of existing drugs against different types
of cancer issues, as well as the increasing emergence of strains
resistant to these drugs are also reported.3 Indeed, one of the
biggest challenges of combating cancer is the development of
new anticancer agents that are safe and effective.
Xanthenones are important biologically active heterocyclic
compounds, with remarkable biological and medicinal pro-
perties, such as antiviral,4 anti-inflammatory,5 antiproliferative6
and antibacterial activities.7 Furthermore these compounds are
also used as dyes,8 as probes for fluorescence-based detection
of biomolecules9 and in laser technologies.10 Xanthenones are
also investigated for agricultural use as bactericide agent7 and
as photosensitizers in photodynamic therapy.11
Multicomponent reaction (MCR) approaches, using a phe-
nolic compound, aldehydes and 1,3-dicarbonyl compounds
under acid-catalyst effect, are used for the synthesis of
xanthones.12–14 In recent years, use of calix[n]arenes as catalyst
has received considerable interest in organic synthesis, par-
ticularly in MCRs.15 Calix[n]arenes are macrocyclic compounds
synthesized by the ortho-condensation of para-substituted
phenols and formaldehyde under base conditions. There are a
large number of applications involving calix[n]arenes due to
their easy structural modification.15–17 In the last two decades,
the chemical literature has reported numerous applications
of calix[n]arenes in supramolecular chemistry.18 Among all
calix[n]arenes known so far, p-sulfonic acid calix[n]arenes showed
to be the most efficient catalysts for Biginelli,19 Povarov,20,21
Mannich-type22 and esterification23 reactions. Although calix
[n]arenes as catalysts in various reactions has been reported,
there is no report in the literature on the use of these com-
pounds as catalysts in the synthesis of xanthenones.
The facile synthesis based on MCR approaches and the
diverse biological profile exhibited by xanthenones brought
new perspectives for the development of new drugs based on
this class of compounds. Herein, we report on the synthesis of
fifty-nine xanthenones, an investigation of their in vitro anti-
proliferative activity on six human cancer cell types and some
structure–activity relationship (SAR) studies.
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Results and discussion
We report herein an easy-to-do and solvent-free three-com-
ponent synthesis of xanthenones in the presence of a catalytic
quantity of the calix[n]arenes CX1–CX6 (Fig. 1). Xanthenones
were synthesized using aldehydes, a 1,3-dicarbonyl compound,
β-naphthol or sesamol as starting materials. First we focused
on the screening of a series of calix[n]arenes (Fig. 1) as cata-
lysts in reactions containing β-naphthol, 4-fluoro-benz-
aldehyde and dimedone at 120 °C under solvent-free
conditions (Table 1). Among the calix[n]arenes tested in the
range of 0.15–2.0 mol%, CX3 and CX6 were the most efficient
catalysts. Both CX3 and CX6 at 1.5 mol% furnished the xanthe-
none 4 in 74% and 68% yields, respectively (Table 1; entries 5
and 10, respectively).
Amounts of CX3 or CX6 lower than 1.0 mol% (Table 1;
entries 2 and 3 for CX3, and entries 7 and 8 for CX6) or higher
than 1.5 mol% (Table 1; entries 6 and 11, for CX3 and CX6,
respectively) provided 4 in poor to moderate yields. The yield
of reactions in the presence of 1.5 mol% calix[n]arenes CX1,
CX2, CX4 or CX5 was comparable to that of catalyst-free reac-
tions (Table 1; entry 1).
We also evaluated whether calix[n]arenes CX3 or CX6 could
be reused in such reactions. After completing the reaction,
CHCl3 and water were added to the mixture in order to recover
CX3 or CX6 in the aqueous phase from the reaction medium.
Once dried, the residue was used in successive reactions in
which the yields were monitored. CX3 and CX6 were success-
fully used in three successive reactions without significant loss
of catalyst activity (Fig. 2).
Considering that yields of reactions in the presence of
either CX3 or CX6 were roughly the same (Table 1, entries 5
and 10, respectively) we chose the former to evaluate the scope
of p-sulfonic acid calix[4]arene for the synthesis of xanthe-
nones. Thus, a variety of aldehydes, 1,3-dicarbonyls and two
phenolic compounds were used (Table 2). Fifty-nine xanthe-
nones (4–62) were synthesized with yields in the range
58–92%. The reaction yields were not considerably affected by
the presence of electron-withdrawing or electron-donating
groups in the aldehydes (Table 2).
Once synthesized, the structural characterizations of the
xanthenones were determined from the corresponding IR,
NMR (1H and 13C) and ESI-HRMS data. Crystals of 4 were also
obtained and its crystal structure was determined using single-
crystal X-ray diffractometry. Crystal data and refinement
results are provided as ESI (Table S1†). Xanthenone 4 crystal-
lizes in the triclinic system (space group P1). Both R and S
enantiomers are present in the chosen crystallographic asym-
metric unit (Fig. 3). Their molecular conformation is similar.
Moreover, they cannot be related by centrosymmetry in the
crystal lattice. Therefore, the crystal structure could not be
solved in the centrosymmetric triclinic space group with only
one molecule in the asymmetric unit. The xanthenone core,
formed with the four fused rings labeled as A–D in Fig. 3, is
approximately planar, except for ring A which assumes a half-
chair conformation with C3 deviating away from the least-
squares plane calculated through the other five coplanar
atoms of this ring by −0.631(7) Å in the R-enantiomer (atom
labels ending with suffix A) and 0.660(6) Å in the S-enantiomer
(atom labels ending with suffix B) (r.m.s.d. of the C2–C1–C6–
C5–C4 fitted atoms is 0.0292 Å in the R-enantiomer and
0.0205 Å in the S-enantiomer). Ring B is not completely planar
in both enantiomers, with C7 carbon deviating by −0.270(6) Å
in the R-enantiomer and 0.212(6) Å in the S-enantiomer
from the least-square mean plane calculated through the
Fig. 1 Structure of calix[n]arenes evaluated as catalyst.
Table 1 Effect of the quantity of p-sulfonic acid calix[n]arenes of
xanthenone 4 based on the amount of catalysta
Entry Catalyst (mol%) Yieldb (%)
1 — 16
2 CX3 (0.15) 53
3 CX3 (0.5) 57
4 CX3 (1.0) 61
5 CX3 (1.5) 74
6 CX3 (2.0) 63
7 CX6 (0.15) 54
8 CX6 (0.5) 61
9 CX6 (1.0) 64
10 CX6 (1.5) 68
11 CX6 (2.0) 67
a Reagents and conditions: β-naphthol/4-fluoro-benzaldehyde/
dimedone (molar ratio of 1.2 : 1.0 : 1.5), 120 °C for 1 h. b Isolated yield.
Fig. 2 Reuse of p-sulfonic acid calix[n]arenes CX3 and CX6 in the syn-
thesis of xanthenone 4.
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C6–C5–O2–C9–C8 atoms (r.m.s.d. of the fitted atoms is
0.0431 Å in the R-enantiomer and 0.0270 Å in the S-enantio-
mer). Taking the xanthenone mean plane as reference, the out-
of-plane C3 and C7 carbons are on the same side of the fluori-
nated phenyl ring in both enantiomers. Another intramolecu-
lar feature common to both enantiomers is the substituted
phenyl ring conformation. Ring E is almost perpendicular to
the xanthenone mean plane, forming an angle of 82.04(12)° in
the R-enantiomer and 84.33(17)° in the S-enantiomer with the
least-square plane calculated through the planar non-hydrogen
atoms of the four fused rings A–D. Therefore, C3 and C7 were
not included in this mean plane calculation.
Antiproliferative activity
Although xanthenones are known as bioactive heterocyclic
compounds, only few works explored the potential of this class
of compounds against cancer cells. Based on this, the antipro-
liferative effect of a series of synthesized xanthenones were
investigated on glioma (U251), breast (MCF-7), multiple drugs-
resistant ovarian (NCI-ADR/RES), renal (786-0), lung non-small
cells (NCI-H460), colon (HT-29), and keratinocyte (HaCaT).
Cell proliferation was determined by the sulforhodamine B
method and doxorubicin (Dox) used as a positive control.24
Initially the fifty-nine xanthenones synthesized were subdi-
vided into two groups of compounds according to the precur-
sor phenol structure. Group 1 consisted of β-naphthol-derived
xanthenones (4–32; Table 2) while 33–62 (Table 2), sesamol
derivatives, were included in Group 2. The concentration of
Table 2 Synthesis of xanthenones catalyzed by the p-sulfonic acid
calix[4]arene CX3a
a Reagents and conditions: phenolic compound/aldehyde/1,3-
dicarbonyl compound (molar ratio of 1.2 : 1.0 : 1.5), 120 °C for 1 h. The
yield for obtaining each xanthenone is presented in parentheses.
Fig. 3 The two crystallographically independent molecules of com-
pound 4. Ellipsoids of 30% probability and arbitrary radius spheres rep-
resent non-hydrogen and hydrogen atoms, respectively. Rings are also
arbitrarily labeled.
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the most active xanthenones that elicited 50% cell growth inhi-
bition (GI50) is summarized in Table 3. The GI50 values for the
remainder of the compounds tested are provided as ESI
(Table S2†).
When analyzing the data obtained for compounds of Group
1 (Table 3) it was noted that the NCI-ADR/RES cell line was the
most sensitive cancer cells as attested by the number of com-
pounds that negatively affected cells growth at GI50 ≤ 10 µg
mL−1 (Table 3). NCI-H460 cells were the least sensitive to com-
pounds of Group 1 (Table 3).
For NCI-ADR/RES nineteen compounds of Group 1 showed
GI50 values lower than 10 μg mL−1. The active compounds of
Group 1 for this strain showed GI50 values in the range of
0.027 to 9.8 μg mL−1. Among the active compounds of Group 1
for NCI-ADR/RES cell line compound 5 was the most potent,
with an GI50 value of 0.027 μg mL−1, its GI50 value was found
to be in the same order of magnitude of that for doxorubicin
(GI50 = 0.047 μg mL−1) (Table 3). Indeed, xanthenone 5 showed
high selectivity index for NCI-ADR/RES cancer cells, presenting
weak antiproliferative activity against non-tumorogenic HaCat
cells (Table 3). Xanthenones 7, 9, 13, 15, 16, 23 and 29 were
also promising against NCI-ADR/RES cells by exhibiting GI50
around 1 μg mL−1 (Table 3). Xanthenones 13, 15, and 29 were
the most potent compounds against NCI-H460 cells; its GI50
value were lower than 5.0 μg mL−1. MCF7 cells were highly sen-
sitive to xanthenones 8, 9, 13–15, 24 and 29 (Table 3). Com-
pounds 13–15, 20 and 29 compromised U251 cell growth by
50% when used at concentrations lower than 6.5 μg mL−1,
while 786-0 cells were sensitive to 4, 6, 8, and 29. For HT-29
cells compounds 13–15, and 29 were the most potent with GI50
values lower than 4.0 μg mL−1. Among the tested compounds
of Group 1, xanthenones 13, 15, 29 were those that exhibited
the largest spectrum of action. These xanthenones showed
considerable antiproliferative activity (GI50 < 10 µg mL
−1)
against all the cancer cell lines, except for kidney cancer cell
line (786-0) in which xanthenones 13 and 15 presented GI50
values of 216.0 and 29.8 µg mL−1, respectively (Table 3).
The second group of xanthenones evaluated (Group 2) is
related with those compounds derived from sesamol (Table 3,
compounds 33–62). The antiproliferative activity of these com-
pounds was expressed as the concentration that produced 50%
cell growth inhibition or a cytostatic effect (GI50, μg mL−1) for
each cell line (Table 3). Data obtained for compounds of
Group 2 (Table 3) shows that MCF7 was the most sensitive
cancer cell line as attested by the number of compounds that
negatively affected cell growth at GI50 ≤ 10 µg mL−1. Nine com-
pounds were active against MCF7, and 48 was the most potent
with GI50 of 0.7 µg mL
−1. Compounds 48 also compromised
U251, NCI-ADR/RES, and HT-29 cells growth by 50% when
used at concentrations lower than 1.0 μg mL−1 while NCI-ADR/
RES cells were sensitive to other six compounds 36, 39, 41, 43
and 45, and 49. For HT-29 cells compounds 41, 45, 49 and 56
were the most potent with GI50 values lower than 4.0 μg mL−1.
Kidney cell line (786-0) was the least sensitive strain to com-
Table 3 Selective index (SI)a and concentration of the most active xanthenones (GI50
b in μg mL−1) that elicits cancer cellsc growth inhibition by 50%
Group Xanthenone
U251 MCF7 NCI-ADR/RES 786–0 NCI-H460 HT-29 HaCaT
GI50 SI GI50 SI GI50 SI GI50 SI GI50 SI GI50 SI GI50
1 4 186.6 0.2 203.7 0.2 2.0 16.1 3.1 10.3 36.3 0.9 >250 <0.1 32.1
1 5 56.8 0.8 92.0 0.5 0.03 1626 28.9 1.5 85.8 0.5 >250 <0.2 43.9
1 6 >250 <0.4 61.4 1.6 >250 <0.4 2.8 35.3 81.7 1.2 >250 0.4 98.9
1 7 29.8 1.8 56.9 1.0 0.8 70.3 >250 <0.2 50.5 1.1 >250 <0.2 54.1
1 8 28.5 0.9 2.0 12.9 227.9 0.1 1.7 15.1 28.7 0.9 48.2 0.5 25.7
1 9 25.6 0.9 5.2 4.5 0.7 33.3 27.1 0.9 31.4 0.7 29.9 0.8 23.3
1 11 14.0 3.8 >250 <0.2 67.5 0.8 225.4 0.2 >250 <0.2 >250 <0.2 52.9
1 13 2.9 2.1 2.6 2.3 0.4 15.2 216.0 0.03 2.8 2.2 3.2 1.9 6.1
1 14 2.9 2.0 2.7 2.1 6.7 0.9 >250 <0.02 13.1 0.4 3.2 1.8 5.8
1 15 2.9 6.9 3.9 5.2 0.3 67.0 29.8 0.7 2.6 7.7 3.4 5.9 20.1
1 16 94.0 2.7 100.3 2.5 0.4 625 197.4 1.3 119.9 2.1 >250 — >250
1 20 6.5 4.4 21.5 1.3 8.9 3.2 20.4 1.4 19.6 1.4 16.0 1.8 28.4
1 21 84.5 2.4 127.0 1.6 51.9 3.9 246.3 0.8 >250 <0.8 >250 <0.8 204.6
1 23 35.1 1.0 82.4 0.4 0.1 341 188.3 0.2 60.3 0.6 95.9 0.4 34.1
1 24 25.1 0.6 8.8 1.8 4.4 3.5 76.6 0.2 44.2 0.3 16.2 1.0 15.4
1 29 2.9 2.4 2.8 2.5 0.4 17.8 4.9 1.4 4.3 1.7 2.9 2.4 7.1
2 36 25.2 1.1 24.4 1.1 9.3 2.9 26.2 1.0 24.3 1.1 19.4 1.4 26.6
2 39 37.2 0.3 5.7 2.3 7.2 1.8 110.3 0.1 27.8 0.5 4.9 2.6 12.9
2 41 3.4 1.2 3.0 1.3 4.9 0.8 4.0 1.0 5.0 0.8 3.5 1.1 4.0
2 43 29.5 1.1 26.3 1.2 8.6 3.8 28.5 1.1 26.1 1.2 25.1 1.3 32.6
2 45 5.3 0.8 3.2 1.3 5.4 0.8 25.0 0.1 10.5 0.4 2.6 1.7 4.3
2 48 0.7 1.1 0.7 1.1 0.5 1.6 2.2 0.4 2.3 0.3 0.43 1.9 0.80
2 49 3.3 0.8 2.2 1.3 1.6 1.8 7.1 0.4 7.3 0.4 2.7 1.0 2.8
2 56 3.3 1.1 2.9 1.2 12.9 0.3 >250 <0.01 3.1 1.1 2.7 1.3 3.5
— Doxd 0.03 7.4 0.06 3.4 0.05 4.0 0.04 5.3 0.01 15.4 0.08 2.4 0.2
a Selectivity index was determined as the ratio of the GI50 for HaCat to the GI50 for the cancer cell line.
bGI50 values were obtained from two
independent experiments, each done in triplicate. cU251, glioma cells; MCF7, breast; NCI-ADR/RES, multiple drug-resistant ovarian cancer cells;
786-0, renal cancer cells; NCI-H460, non-small lung cancer cells; HT-29, colon cancer cells; HaCaT, keratinocyte. d Reference drug.
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pounds of Group 2, as for this line only compounds 41, 48 and
49 were active, with GI50 values of 4.0, 2.2 and 7.1 µg mL
−1,
respectively. For NCI-H460 strain compounds 41, 48, 49 and 56
were active compounds of Group 2. Compounds 48 (GI50 = 2.3
µg mL−1) and 56 (GI50 = 3.1 µg mL
−1) exhibited GI50 values
lower than 4.0 µg mL−1, thus showing potent anticancer
activity. Among compounds of Group 2, 41, 48 and 49 were
those showing the highest spectrum of action, which were
active against the six cancer cell lines evaluated. Compound 48
showed GI50 values lower than 4.0 µg mL
−1 for all tested
strains and can therefore be described as the most promising
compound among compounds of Group 2.
The selectivity index (SI) was calculated for each compound
of Group 1 and 2 (Table 3). Among evaluated xanthenones,
compound 5 showed the highest SI value for NCI-ADR/RES
cells, which indicated the potential use of this compound for
future in vivo tests.
When comparing the results obtained for compounds of
Group 1 and 2, we can see that in general compounds of
Group 1 were more active than the compounds of Group
2. Among compounds of Group 1 evaluated eight compounds
showed no activity against any of the tested strains, whereas
eighteen compounds of Group 2 were inactive for all cell lines
evaluated. Together these results suggest that the naphthyl
nucleus is important for the antiproliferative activity of this
class of compound. Overall, the potency of xanthenones was
dependent on the histological origin of cancer cells.
QSAR studies
For a more careful analysis of the relationship between mole-
cular structure and biological activity, QSAR studies were per-
formed. To determine the correlation between molecular
descriptors and the efficiency of the set of xanthenones, we
tested a set of models as discussed below.
At first, a structural analysis of the studied compounds was
carried out. The geometries of the 59 synthesized compounds
were obtained from AM1 semiempirical calculations, after a
conformational analysis using the conformer distribution sub-
routine of the SPARTAN’06 software. The most stable confor-
mation of each derivative was then reoptimized with MOPAC
software, again using the AM1 method. The output files from
the MOPAC calculation were used to generate a set of mole-
cular descriptors by using the CODESSA software.
CODESSA may generate about 400 molecular descriptors
associated with molecular constitution, geometry, and topo-
logy and with electrostatic, thermodynamic, and quantum
chemical parameters. The molecular descriptors generated by
CODESSA were correlated to the biological efficiency using the
heuristic method.25 Models based on a single molecular
descriptor were chosen to obtain statistically significant mean-
ings. After elimination of descriptors with low variance or high
intercorrelation, the best correlations were found with the
molecular descriptors for compounds of Group 1 to cell lines
U251 and NCI-H460. Compounds with GI50 > 250 µg mL
−1
were not considered in the QSAR studies.
For U251 the best correlation was between experimental
biological activity of compounds of Group 1 and the calculated
efficiency based on the molecular descriptor HDCA-1.
HDCA-1 is a molecular descriptor that reports the hydrogen
bonding donor ability of the molecule. The values of this
descriptor are obtained as a sum of the accessible surface area




sD D [ HH-donor
where sD – solvent-accessible surface area of H-bonding donor
H atoms.
The model obtained for U251 cells is given in Fig. 4 with
the corresponding calculated efficiency versus measured
efficiency plot.
This correlation indicates that increasing the accessible
surface area of hydrogen bond donor atoms (HDCA1) leads to
an increase in biological activity of the compound. This model
shown to be consistent with the fact that compounds 13, 14,
15, and 29, which have a hydroxyl group in the meta or para
position and have the highest values of HDCA1 molecular
descriptor, were the most active against U251 cells. Although
compounds 11 and 21 possess a hydroxyl group in the ortho
position, this is less accessible than the meta or para positions






¼ 6:49 101ð+8:41 102ÞðHDCA1Þ
 2:46 10ð+1:01 101Þ
n ¼ 23; r2 ¼ 0:764; F ¼ 68:1; s2 ¼ 0:1067; Rcv2 ¼ 0:731
The best correlation found for NCI-H460 cells was between
the experimental biological activity of compounds of Group 1
and the calculated efficiency based on the molecular descrip-
tor HDCA2. HDCA2 is a molecular descriptor based on accessi-
ble area of hydrogen-bond donor atoms and corresponds to











p D [ HH-donor
Fig. 4 Experimental versus calculated efficiency with the HDCA1
descriptor.
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where sD – solvent-accessible surface area of H-bonding donor
H atoms; qD – partial charge on H-bonding donor H atoms;
Stot – total solvent-accessible molecular surface area.
The model obtained for NCI-H460 cells is given in Fig. 5.
This relation indicates that the activity values increase when
increasing the value of the molecular descriptor HDCA2. This
behavior is similar to that shown for U251 cells and the
HDCA1 molecular descriptor. Again compounds 13, 14, 15,
and 29, which have a hydroxyl group in the meta or para posi-
tions and have the highest values of HDCA2 molecular descrip-
tor, were the most active against NCI-H460 cells and ortho
hidroxilated compounds 11 and 21 were less active than meta
or para hydroxylated derivatives. In summary, these two
models shows that the activity of compounds of Group 1
against U251 and NCI-H460 increased with increase in accessi-





¼ 4:00 10ð+5:06 101ÞðHDCA2Þ
 2:74 10ð+1:39 101Þ
n ¼ 22; r2 ¼ 0:758; F ¼ 62:5; s2 ¼ 0:159; Rcv2 ¼ 0:639
Conclusions
An efficient method was described for the synthesis of fifty
nine xanthenones under mild conditions. The reaction yields
dramatically increased upon the use of p-sulfonic acid calix[n]-
arenes as catalysts. Some advantages of the approach here
described include absence of solvents and metal catalysts,
short reaction time, catalyst tolerance of a wide range of func-
tional groups and catalyst recycling as well. The ability to
inhibit the growth of cancer cells was also investigated for the
synthesized compounds. Compound 5 was as potent as the
reference drug doxorubicin against NCI-ADR/RES and present
the greater value of SI. Several compounds were shown to be
active against different cancer cell lines indicating that the
capacity to inhibit cancer cell growth of the xanthenones was
dependent on the histological origin of cells. In general,
xanthenones derivatives of β-naphthol were more active than
those derived from sesamol. A QSAR study was performed and
two QSAR models were obtained for compounds of Group 1
against U251 and NCI-H460 cells and indicated that the bio-
logical activity of the compounds increased with increasing
accessible surface area of hydrogen bond donor atoms. These
results show some xanthenones as lead compounds for obtain-
ing new anticancer agents.
Experimental
General methods and materials
All starting materials were obtained from commercially avail-
able sources with high-grade purity and used without further
purification. Calix[n]arenes CX1–CX6 were prepared according
to known procedures.28–30 Reactions did not require anhydrous
conditions. The melting points (uncorrected) of synthesized
xanthenones were determined on a Mettler FP 80 HT appar-
atus. Infrared spectra were recorded on a Perkin-Elmer Spec-
trum One spectrophotometer (KBr). The 1H and 13C-NMR
spectra were recorded on a Bruker AVANCE DPX-200 spec-
trometry at 200 MHz to 1H and 50 MHz to 13C, in DMSO-d6,
CDCl3 or pyridine-d5. Coupling constants ( J) are reported in
Hertz (Hz). High resolution mass spectra (HRMS) were
recorded on Shimadzu LC-IT-TOF Prominence system. Low
temperature X-ray diffraction data were collected using an
Enraf-Nonius Kappa-CCD diffractometer equipped with a CCD
camera of 95 mm and κ-goniostat. No absorption correction
was applied to the raw dataset due to the negligible absorption
coefficient using graphite-monochromated Mo Kα beam (λ =
0.71073 Å). The structure was solved using the direct methods
of phase retrieval and the model was refined by full-matrix
least squares method based on F2. Positions of hydrogens have
followed a riding model with bond distances stereochemically
constrained according to the bonded carbon. The isotropic
thermal displacement parameters of hydrogens were either
20% (C–H hydrogens, except those in methyl moieties) or 50%
(hydrogens in methyl moieties) greater than the equivalent iso-
tropic parameter of the bonded carbon.
General procedure for the synthesis of xanthenones
A mixture of an aromatic aldehyde (1 mmol), 1,3-dicarbonyl
compound (1.5 mmol) and β-naphthol or sesamol (1.2 mmol)
and p-sulfonic acid calix[n]arene CX3 or CX6 (1.5 mol%) was
stirred at 120 °C for 1 h. After completion of the reaction,
methanol was added to the mixture and stirred for 30 min.
Then the solid was filtered and washed with cold ethanol to
afford the xanthenones 4–62 in high purity (Table 3). All
xanthenones were characterized by 1H, 13C NMR, IR, HRMS
(ESI) and melting point (see ESI† for reference).
Antiproliferative assay
Human tumor cell lines U251 (glioma), MCF-7 (breast)
NCI-ADR/RES (multiple drugs-resistant ovarian), 786-0 (renal),
NCI-H460 (lung, non-small cells), HT-29 (colon), and HaCaT
(keratinocyte) were kindly provided by Frederick Cancer
Research & Development Center-National Cancer Institute-
Fig. 5 Experimental versus calculated efficiency with the HDCA2
descriptor.
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Frederick, MA, USA. Stock cultures were grown in RPMI 1640
(GIBCO BRL, Life Technologies) supplemented with 5% of
fetal bovine serum and penicillin (final concentration of 1 mg
mL−1) and streptomycin (final concentration of 200 U
mL−1).31,32 Cells in 96-well plates (100 μL cells per well) were
exposed to xanthenones (0.25–250 μg mL−1) for 48 h at 37 °C
and 5% of CO2. Afterward cells were fixed with 50% trichloro-
acetic acid, submitted to sulforhodamine B assay for cell pro-
liferation quantitation at 540 nm.24 The concentration of
compound that inhibits cell growth by 50% (GI50) was deter-
mined through non-linear regression analysis using software
ORIGIN 7.5 (OriginLab Corporation). Doxorubicin was used as
a reference drug. Results presented are from two independent
experiments, each done in triplicate.
Computations
The conformational analysis of the 59 xanthenones was done
using the conformer distribution subroutine of the
SPARTAN’06 software.33 The most stable conformation of each
derivative was selected for further calculations with the
MOPAC code,34 again using the AM135 semiempirical method.
In this new step the geometry optimization was developed with
the MOPAC code and all structures were confirmed as a local
minimum by calculation of the Hessian matrix force constant
(no negative eigenvector).36 Two sets of output files were
obtained with the MOPAC code. In the first one the following
keywords were used: AM1, PRECISE, XYZ, EF, ENPART,
VECTORS, BONDS, PI, and POLAR. In the second one, which
was used to calculate the thermodynamic properties, the fol-
lowing keywords were used: AM1, PRECISE, THERMO, ROT =
1, and XYZ. These output files from MOPAC calculations were
used to the development of the initial CODESSA calculations,
to generate a set of molecular descriptors used in the QSAR
analysis, also developed by using the CODESSA software.37 In
the statistical analysis for the QSAR study the following para-
meters were employed: maximum number of descriptors per
model, 1; criterion of significance of parameter, 0.01; level of
high correlation, 0.99; level of intercorrelation significance, 0.8.
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